As of Thursday close, Abbott Laboratories’s (NYSE:ABT) stock was up $0.11, moving up 0.10 percent to $109.72. The average number of shares traded per day over the past five days has been 3,709,760 shares. 3 times new highs have been achieved over the past 5 days, with a -$0.64 fall in that time frame. In the last twenty days, the average volume was 4,547,510, while in the previous 50 days, it was 4,939,698.
Since last month, ABT stock rose 0.95%. Shares of the company fell to $103.76 on 07/14/22, the lowest level in the past month. A 52-week high of $142.60 was reached on 01/03/22 after having rallying from a 52-week low of $101.24. Since the beginning of this year, ABT’s stock price has dropped by -22.04% or -$31.02, and marked a new high 1 time. However, the stock has declined by -23.06% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Abbott Laboratories (ABT) last reported insider trading activity 10 days ago on Jul 26. STARKS DANIEL J, the Director of the company, disposed of 50,000 shares for $109.14 on Jul 26. It resulted in a $5,456,994 divestment by the insider. Mateus Fernando sold 2,457 shares at an average price of $109.05 on Jul 26. The insider now owns 14,503 shares following the transaction. On Jul 25, SENIOR VICE PRESIDENT Tyler Julie L. sold 253 shares at $109.09 apiece. The transaction was valued at $27,600.
Right now, Abbott Laboratories (ABT) has a P/E ratio of about 22.80. The stock’s beta is 0.72. Besides these, the trailing price-to-sales (P/S) ratio of 4.26, the price-to-book (PB) ratio of 5.46, and the price-to-cash flow ratio of 35.65 may also be considered.
The latest dividend of $0.47 per share was paid out, remained unchanged from last year’s $0.47. On Friday December 10 2021, a $0.02 dividend increase was announced.
In the three months ended June 29, Abbott Laboratories’s quick ratio stood at 1.40, while its current ratio was 1.90, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.48, and the total debt-to-equity ratio was 0.48. On the profitability front, the trailing twelve-month gross margin is 58.10% percent. In the year ended June 29, operating margins totaled 18.50%. Based on annual data, ABT earned $24.54 billion in gross profit and brought in $43.08 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 13.50%. Return on equity (ROE) for the past 12 months was 20.30%.
In Abbott Laboratories’s quarter-end financial report for June 29, it reported total debt of $16.75 billion against cash and short-term investments of $353.0 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ABT’s revenue rose 9.19% to $11.89 billion during the quarter, while net income inched up to $11.26 billion. While analysts expected Abbott Laboratories to report $1.13 quarterly earnings, the actual figure was $1.43 per share, beating the consensus estimate by 26.50%. During the quarter, the company generated $3.2 billion in EBITDA. The liabilities of Abbott Laboratories were 37.49 billion at the end of its most recent quarter ended June 29, and its total debt was $17.12 billion. The value of shareholders’ equity is $1.75 billion.
This quick technical analysis looks at Abbott Laboratories’s (ABT) price momentum. With a historical volatility rate of 12.10%, the RSI 9-day stood at 53.49% on 04 August.
With respect to its five-day moving average, the current Abbott Laboratories price is down by -0.58% percent or -$0.64. At present, ABT shares trade +0.21% above its 20-day simple moving average and -3.77% percent below its 100-day simple moving average. However, the stock is currently trading approximately -4.62% below its SMA50 and -6.08% below its SMA200.
Stochastic coefficient K was 57.04% and Stochastic coefficient D was 60.66%, while ATR was 2.12. Given the Stochastic reading of 56.98% for the 14-day period, the RSI (14) reading has been calculated as 51.82%. As of today, the MACD Oscillator reading stands at -0.04, while the 14-day reading stands at 0.08.
Wolfe Research launched its rating on Abbott Laboratories (NYSE: ABT) to an Underperform in a note to investors on July 06, 2022. Abbott Laboratories (ABT) has been rated Overweight by analysts. According to 2 brokerage firms, ABT is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 4 analysts rate Abbott Laboratories stock as buy, with 13 recommending it as overweight.
With a median target price of $126.00, the current consensus forecast for the stock is $95.00 – $150.00. Based on these forecasts, analysts predict Abbott Laboratories (ABT) will achieve an average price target of $124.65.